Molbio's maiden post-IPO print: consol. PAT ₹52.7 Cr, YoY surge off a weak base

Molbio Diagnostics reported its first quarterly result as a listed company for Q1 FY27 (quarter ended June 30, 2026). Consolidated revenue was ₹408.4 Cr, up ~309.6% YoY from ₹99.7 Cr in Q1 FY26, and the group swung to a consolidated profit of ₹52.7 Cr (owners' share ₹58.7 Cr, EPS ₹5.21) versus a loss of ₹23.9 Cr a year earlier — a clear YoY turnaround. Sequentially, however, revenue fell 27.2% and group PAT fell ~45% from the ₹560.6 Cr revenue / ₹95.8 Cr PAT posted in Q4 FY26 (Mar'26). The headline YoY jump needs context: Q1 FY26's ₹99.7 Cr revenue was barely a quarter of the ₹363.8 Cr average quarterly run-rate implied by FY26's full-year consolidated revenue of ₹1,455.7 Cr, so last year's June quarter was an unusually weak base rather than a normal comparator — the 3x YoY headline overstates underlying momentum, and the FY26 quarterly pattern (weak June quarter, much stronger March quarter) suggests this is a recurring seasonal shape for the business, not a one-off.

On margins, consolidated PBT margin was 18.6% of revenue versus −31.4% a year ago (turnaround) but down from 23.5% in Q4 FY26 — the sequential compression tracked the revenue pullback rather than any cost blowout (total expenses fell 27.4% quarter-on-quarter, roughly matching the revenue decline). The gap between the group's total PAT (₹52.7 Cr) and the ₹58.7 Cr attributable to Molbio's own shareholders comes from a negative ₹6.0 Cr non-controlling interest: the four consolidated subsidiaries (Bigtec, OptraScan Inc, OptraScan India, Prognosys Medical/Healthcare) posted a combined net loss of ₹13.0 Cr this quarter per the auditors' review, so losses at these units are being absorbed disproportionately by minority shareholders, flattering the parent's own profit relative to the group total. Standalone (parent-only) numbers were broadly consistent — revenue ₹399.4 Cr, PAT ₹56.6 Cr, EPS ₹5.02.

No exceptional items this quarter (FY26 full year carried a ₹4.85 Cr consolidated exceptional item); a disputed ₹20.87 Cr income-tax demand (AY20-21 to 24-25) remains unprovided

There is no street consensus or prior management guidance to benchmark this print against: Molbio listed on the NSE and BSE only on August 17, 2026 (a ₹939.7 Cr issue — ₹200 Cr fresh issue plus a ₹739.7 Cr offer-for-sale — subscribed 70.27x), so this is its maiden disclosure as a public company and no brokerage previews or analyst estimates for the quarter could be found. No press release or management commentary accompanied this filing, so there is no management framing to reconcile against the numbers. Other developments in the quarter — a compliance officer appointment (Aug 27) and a routine insider-trading window closure (Aug 20) — are administrative and don't bear on the print. Separately, the company disclosed a contingent tax demand of ₹20.87 Cr from an income-tax survey covering AY2020-21 to 2024-25, under appeal and not provided for in these results.